Literature DB >> 8001025

Differences in biodistribution of the anti-(carcinoembryonic antigen) murine monoclonal antibody CE-25, its F(ab')2 fragment and its intact mainly human chimeric form CE 4-8-13. Dependence on tumour size and amount of antibody injected.

G Westera1, T Rülicke, A Smith, S Duewell.   

Abstract

The effect of the size of the tumour and the amount of antibody injected on the biodistribution of a family of radioiodinated antibodies was studied. The intact mouse anti-(carcinoembryonic antigen) (anti-CEA) monoclonal antibody CE-25, its F(ab')2 fragment and the intact human-mouse chimeric from CE 4-8-13 were evaluated in a model system using the human CEA-producing colon xenograft T 380 grown in nude mice. The relative retention (the percentage of the injected dose per gram of tissue), of mouse mAb and F(ab')2 in tumour and most normal tissues 1 day after injection was independent of the antibody dose; after 4 days the mAb values increased with increasing antibody dose. The relative retention of chimeric mAb increased with increasing antibody dose 1 day after injection and also slightly after 4 days. The relative retention in tumour tissue was lower in bigger xenografts for all antibodies. The relative retention of mouse mAb in small tumours increased from day 1 to day 4; for chimeric mAb this value decreased. In normal tissues the relative retention of mouse mAb decreased from day 1 to day 4, but the relative retention of chimeric mAb in normal tissue dropped rapidly and changed little afterwards. Thus the biokinetics of antibodies is "species"-dependent: foreign, mainly human, chimeric antibody clears faster from normal mouse tissue than mouse antibody and reaches lower concentrations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001025     DOI: 10.1007/BF01534424

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice.

Authors:  Y Watanabe; K Endo; M Koizumi; Y Kawamura; T Saga; H Sakahara; M Kuroki; Y Matsuoka; J Konishi
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

2.  Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.

Authors:  J F Chatal; J C Saccavini; J F Gestin; P Thédrez; C Curtet; M Kremer; D Guerreau; D Nolibé; P Fumoleau; Y Guillard
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

3.  Human breast tumor imaging using 111In labeled monoclonal antibody: athymic mouse model.

Authors:  B A Khaw; J S Bailes; S L Schneider; J Lancaster; J Powers; H W Strauss; J C Lasher; W L McGuire
Journal:  Eur J Nucl Med       Date:  1988

4.  Effect of unlabelled monoclonal antibody (MoAb) on biodistribution of 111indium labelled (MoAb).

Authors:  L M Lamki; J L Murray; M G Rosenblum; Y Z Patt; R Babaian; M W Unger
Journal:  Nucl Med Commun       Date:  1988-08       Impact factor: 1.690

5.  The effects of tumor mass, tumor age, and external beam radiation on tumor-specific antibody uptake.

Authors:  J Y Wong; L E Williams; L R Hill; R J Paxton; B G Beatty; J E Shively; J D Beatty
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

6.  Different behaviour of mouse-human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub-class in vivo.

Authors:  F Buchegger; A Pèlegrin; N Hardman; C Heusser; J Lukas; W Dolci; J P Mach
Journal:  Int J Cancer       Date:  1992-02-01       Impact factor: 7.396

7.  Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen.

Authors:  N Hardman; L L Gill; R F De Winter; K Wagner; M Hollis; F Businger; D Ammaturo; F Buchegger; J P Mach; C Heusser
Journal:  Int J Cancer       Date:  1989-09-15       Impact factor: 7.396

8.  Effect of dose escalation of a monoclonal anti-CEA IgG on tumour localisation and tissue distribution in nude mice xenografted with human colon carcinoma.

Authors:  G T Rogers; R B Pedley; J Boden; P J Harwood; K D Bagshawe
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected dose.

Authors:  S Duewell; W Horst; G Westera
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

10.  Localization and imaging of radiolabeled monoclonal antibodies against colorectal carcinoma in tumor-bearing nude mice.

Authors:  D Buchsbaum; R Lloyd; J Juni; I Wollner; P Brubaker; D Hanna; J Spicker; F Burns; Z Steplewski; D Colcher
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.